ArQule to Report Third Quarter 2013 Financial Results on November 7, 2013
WOBURN, Mass. -- October 31, 2013
ArQule, Inc. (NASDAQ: ARQL) today announced that it will report its financial
results for the third quarter of 2013 on Thursday, November 7, 2013 at 7:00
a.m. Eastern Time. The Company will hold a conference call at 9:00 a.m.
Eastern Time that day to discuss these results.
Conference Call and Webcast
Date: Thursday, November 7, 2013
Time: 9:00 a.m., Eastern Time
Conference Call Numbers
Domestic (toll free): (877) 868-1831
International: (914) 495-8595
A replay of the conference call will be available beginning two hours after
the completion of the call through November 9, 2013 and can be accessed by
dialing toll-free 855-859-2056 or 800-585-8367 and from outside the U.S.
404-537-3406. The confirmation code for replayed calls is 86068331.
ArQule is a biotechnology company engaged in the research and development of
next-generation, small-molecule cancer therapeutics. The Company’s targeted,
broad-spectrum products and research programs are focused on key biological
processes that are central to human cancers. ArQule’s lead product, in Phase 2
and Phase 3 clinical development, is tivantinib (ARQ 197), an oral, selective
inhibitor of the c-MET receptor tyrosine kinase. The Company’s pipeline
includes: ARQ 092, designed to inhibit the AKT serine/threonine kinase, and
ARQ 087, designed to inhibit fibroblast growth factor receptor (FGFR).
ArQule’s current discovery efforts, which are based on the ArQule Kinase
Inhibitor Platform (AKIP™), are focused on the identification of novel kinase
inhibitors that are potent, selective and do not compete with ATP (adenosine
triphosphate) for binding to the kinase.
William B. Boni, 781-994-0300
VP, Investor Relations/
Press spacebar to pause and continue. Press esc to stop.